Business Context and Reporting Period
Company: GSK Plc (GlaxoSmithKline plc)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter ended March 31, 2022
Issuance Date: April 27, 2022
GSK reported strong Q1 2022 results, driven by significant sales growth in Biopharma and Consumer Healthcare. The company is on track to demerge its Consumer Healthcare business into a new entity, Haleon, in July 2022. The results reflect a strategic shift toward a science-led biopharma company focused on the immune system, human genetics, and advanced technologies.
Key Financial Metrics
| Metric | Q1 2022 | Q1 2021 | Growth (AER) | Growth (CER) |
|---|---|---|---|---|
| Turnover | £9.78 billion | £7.42 billion | +32% | +32% |
| Total Operating Profit | £2.80 billion | £1.69 billion | +65% | +65% |
| Adjusted Operating Profit | £2.61 billion | £1.88 billion | +39% | +39% |
| Total EPS | 35.9p | 21.5p | +67% | +66% |
| Adjusted EPS | 32.8p | 22.9p | +43% | +43% |
| Cash from Operations | £2.76 billion | £0.49 billion | >100% | N/A |
| Free Cash Flow | £1.65 billion | (£3 million) | >100% | N/A |
| Net Debt | £19.35 billion | £21.40 billion | - | - |
Note: AER = Actual Exchange Rates; CER = Constant Exchange Rates.
Material Changes vs. Prior Period
- Revenue Surge: Turnover increased 32% (CER), primarily driven by Commercial Operations (+40% CER). Specialty Medicines grew 98% (CER) and Vaccines grew 36% (CER).
- COVID-19 Solutions Impact: Sales of Xevudy (sotrovimab) reached £1.3 billion in Q1 2022, contributing approximately 25 percentage points to Commercial Operations growth. However, management expects reduced profit contribution from COVID-19 solutions in the remainder of 2022 due to lower margins and regulatory changes regarding the Omicron variant.
- One-Time Income: Total operating profit included a £924 million upfront settlement income from Gilead Sciences regarding patent litigation, significantly boosting Total EPS.
- Cost Structure: Adjusted operating margin improved to 26.7% (up 1.3 percentage points CER) due to tight cost control and restructuring benefits, despite higher supply chain and commodity costs.
- Consumer Healthcare: Turnover grew 14% (CER) to £2.63 billion, with strong performance in Pain Relief and Respiratory Health categories ahead of the July demerger.
Guidance, Outlook, and Risks
2022 Guidance (New GSK)
GSK reconfirmed its full-year 2022 guidance for the post-demerger entity (excluding Consumer Healthcare and COVID-19 solutions):
- Sales Growth: 5% to 7% at CER.
- Adjusted Operating Profit Growth: 12% to 14% at CER.
Management Commentary
CEO Emma Walmsley highlighted strong momentum in Specialty Medicines and Vaccines, particularly the recovery of Shingrix sales. The company expects Specialty Medicines to grow approximately 10% CER in 2022, while General Medicines may see a slight decrease due to generic competition. Vaccines are expected to grow at a low-teens percentage.
Risks and Contingencies
- COVID-19 Variants: The US FDA updated Xevudy's authorization in April 2022, removing authorization for treatment in any US region due to the Omicron BA.2 sub-variant. Future sales depend on new variants and government agreements.
- Demerger Execution: The separation of Consumer Healthcare (Haleon) is scheduled for July 2022. Delays or complications could impact financial reporting and operational efficiency.
- Legal and Regulatory: Ongoing litigation and regulatory approvals for pipeline assets (e.g., daprodustat, Blenrep, Jemperli) carry inherent uncertainty.
- Supply Chain: Continued inflation in commodity prices and freight costs remains a pressure point.
Investor Verification Checklist
- Xevudy Sustainability: Verify the impact of the FDA authorization update on future Xevudy revenue and the timeline for potential new variant approvals.
- Gilead Settlement: Confirm the sustainability of the £924 million one-time income and the long-term royalty stream from the Gilead agreement.
- Haleon Demerger: Monitor the July 2022 demerger timeline and the specific dividend policy for the new Consumer Healthcare entity.
- Pipeline Milestones: Track upcoming Phase III data readouts for RSV Older Adults, MenABCWY, Blenrep, and Jemperli scheduled for the remainder of 2022.
- Shingrix Growth: Assess whether the >100% growth in Shingrix is sustainable or driven by channel inventory build-up.